HPCSA-registeredSAHPRA-authorisedPOPIA-secure

Docto24
Sign inCHECK ELIGIBILITY
ME/CFS (Myalgic encephalomyelitis / chronic fatigue syndrome) — medical cannabis evaluation

Condition · ICD-11 8E49

ME/CFS (Myalgic encephalomyelitis / chronic fatigue syndrome)

Reviewed by Dr. Placeholder B (HPCSA MP0XXXXX · Pain Medicine) · Last updated · Published

Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) is a chronic multi-system condition characterised by post-exertional malaise (PEM), unrefreshing sleep, cognitive impairment, and widespread pain, often following a viral infection. There is no curative treatment and management focuses on pacing, symptom control, and avoiding harm — particularly avoiding graded exercise programmes, which are now contraindicated in ME/CFS by major international guidelines. Cannabinoid therapy is sometimes considered for adjunctive symptomatic management — pain, sleep, anxiety — and it is offered with explicit honesty: it is not a treatment for ME/CFS, it does not address the underlying pathology, and the evidence base is largely extrapolated from chronic-pain and fibromyalgia data rather than ME/CFS-specific trials.

What the evidence says

There are no high-quality randomised trials of cannabinoids specifically for ME/CFS. The clinical use case is extrapolated primarily from chronic-pain and fibromyalgia data, where cannabinoid therapy has shown modest symptomatic benefit in refractory cases. NICE 2021 ME/CFS guideline (UK) does not endorse cannabinoids but explicitly emphasises that energy management (pacing) and avoiding harmful interventions are the foundations of care. ME/CFS-patient cohort surveys consistently report that those who try cannabis-based products commonly cite pain and sleep benefit, but selection bias and lack of controls limit what can be concluded. The honest summary: there is no direct evidence cannabinoids help ME/CFS itself; there is indirect, weak evidence they may help selected patients with refractory pain or sleep components.

How the doctor will evaluate you

You will need a clinical history consistent with ME/CFS diagnostic criteria (typically International Consensus Criteria or NICE 2021 framework), exclusion of alternative diagnoses (thyroid, sleep apnoea, depression, autoimmune workup), and an explicit identification of which symptom is targeted by the cannabinoid trial (almost always pain or sleep). The doctor will not recommend graded exercise as part of the management plan and will explicitly avoid any "push through it" framing. Cannabinoid dosing is more conservative than in chronic-pain populations because ME/CFS patients are particularly sensitive to medication side effects. CBD-leaning regimens are the typical starting point with very low THC if any.

When to see a doctor urgently

  • No diagnostic workup excluding alternative causes — investigate fatigue properly before symptomatic adjunct
  • Major depressive episode mimicking ME/CFS — psychiatric assessment first
  • Worsening post-exertional malaise on current activity level — pacing review takes priority over cannabinoid initiation
  • New focal neurological symptoms or unexplained weight loss — alternative diagnosis must be excluded

If any of the above apply, seek in-person medical care — do not wait for a remote Section 21 consultation.

The South African Section 21 pathway

ME/CFS is an uncommon Section 21 indication in South Africa, framed in the application as adjunctive management for refractory pain or sleep disturbance specifically — not as ME/CFS treatment. Applications are stronger when supported by a clinical history fitting standard diagnostic criteria, documented exclusion of alternative causes, and clear targeting of a specific symptom. Authorisations are conservative and reviewed at renewal against measurable symptomatic improvement.

Frequently asked

Will medical cannabis cure my chronic fatigue?
No. There is no evidence — and no cannabinoid mechanism known — to suggest it treats the underlying ME/CFS pathology. Where it may help is with specific symptom components: refractory pain, sleep disturbance, or anxiety. We are honest with patients about this distinction.
Will it give me more energy?
Often the opposite — cannabinoids can be sedating, particularly THC at higher doses. The clinical aim is rarely "energise"; it is "improve sleep quality and reduce pain so daytime function is less depleted by symptom burden". Patients seeking a stimulant effect are not a fit for cannabinoid therapy.
I have ME/CFS — will the doctor recommend exercise?
No. Graded exercise therapy is no longer recommended in ME/CFS by major guidelines, and we follow that. Pacing, energy-envelope management, and symptomatic adjuncts are the framework. Any clinician pushing graded exercise as a treatment for ME/CFS is operating outside current evidence.
Can I take it during a post-exertional crash?
Some patients find low-dose CBD helps modulate the pain and sleep disturbance components of post-exertional malaise (PEM). It will not abort the crash itself — PEM is driven by the underlying ME/CFS pathophysiology, which cannabinoids do not affect. The most important intervention during a crash remains rest, pacing-down, and avoiding further exertional load.
How does this compare with low-dose naltrexone (LDN)?
LDN is sometimes used in ME/CFS for pain and immune-modulation effects with mixed evidence. The two work via entirely different mechanisms and can be co-prescribed in some cases. The Docto24 doctor will not initiate LDN — that sits with whoever prescribes it currently — but will check for any interactions or overlapping side-effect profiles when starting cannabinoid adjunct.

Related conditions

Glossary — terms used on this page

Quick definitions for terminology referenced above. Each links to a fuller entry.

Think this might apply to you? An HPCSA-registered doctor will review your case.

START ELIGIBILITY REVIEW

R500 consultation · R400 SAHPRA fee per product · 3–7 days end-to-end